NASDAQ:LNCR - Lincare Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Lincare Holdings Inc. (Lincare) is a provider of oxygen, respiratory and other chronic therapy services to patients in the home. The Company's customers suffer from chronic obstructive pulmonary disease (COPD), such as emphysema, chronic bronchitis or asthma, and require supplemental oxygen, respiratory and other chronic therapy services. As of December 31, 2011, the Company served more than 800,000 customers in 48 states of the United States and Canada through 1,108 operating centers. Lincare primarily provides oxygen, respiratory and other chronic therapy services to patients in the home. It also provides a variety of durable medical equipment (DME) and home infusion therapies in certain geographic markets. During the year ended December 31, 2011, the Company acquired companies that were contracted to provide home oxygen equipment and positive airway pressure devices. In August 2012, Lincare announced that The Linde Group completed its previously announced acquisition of the Company.

Receive LNCR News and Ratings via Email

Sign-up to receive the latest news and ratings for LNCR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:LNCR
Previous Symbol
CUSIPN/A
Phone+1-813-5307700

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Lincare (NASDAQ:LNCR) Frequently Asked Questions

What is Lincare's stock symbol?

Lincare trades on the NASDAQ under the ticker symbol "LNCR."

Has Lincare been receiving favorable news coverage?

News articles about LNCR stock have trended somewhat positive on Friday, InfoTrie reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Lincare earned a media sentiment score of 1.1 on InfoTrie's scale. They also gave news headlines about the healthcare company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Lincare?

Shares of LNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lincare's official website?

The official website for Lincare is http://www.lincare.com.

How can I contact Lincare?

Lincare's mailing address is 19387 US Highway 19 N, CLEARWATER, FL 33764-3102, United States. The healthcare company can be reached via phone at +1-813-5307700.


MarketBeat Community Rating for Lincare (NASDAQ LNCR)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  152
MarketBeat's community ratings are surveys of what our community members think about Lincare and other stocks. Vote "Outperform" if you believe LNCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LNCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel